MetaCap

Evommune Inc. Company Profile

NYSE: EVMNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.04-0.20 (-2.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Evommune at a glance

Evommune Inc. (NYSE: EVMN) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Palo Alto, CA. Evommune is led by Mr. Luis C. Pena and employs about 48 people. The company's shares have traded publicly since 2025.

At a market capitalization of $291.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0002044725, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Evommune do?

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Business description based on the company's public filings.

Company information

Legal name
Evommune Inc.
Ticker
NYSE: EVMN
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Luis C. Pena
Employees
48
Headquarters
1891 Page Mill Road, Palo Alto, CA, United States
Phone
(925) 247-4481
IPO year
2025
Market cap
$291.10M
SEC CIK
0002044725

Companies similar to Evommune

EVMN peer companies
CompanyPrice% ChgMarket capCompare
BNTCBenitec Biopharma Inc.7.92-2.76%$285.88Mvs EVMN
SPRYARS Pharmaceuticals Inc.2.96-11.90%$297.56Mvs EVMN
GLSIGreenwich LifeSciences Inc.19.25-2.73%$282.56Mvs EVMN
FULCFulcrum Therapeutics Inc.3.69-0.54%$281.85Mvs EVMN
RLMDRelmada Therapeutics Inc.2.62-15.76%$279.54Mvs EVMN
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs EVMN
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs EVMN
AVIRAtea Pharmaceuticals Inc.3.96+0.76%$318.00Mvs EVMN

Related